Baird Downgrades Exactech (EXAC) to Neutral
More News related to EXAC
- Baird Upgrades Exactech (EXAC) to Outperform
- Exactech (EXAC) Tops Q3 EPS by 1c; Issues Mixed Guidance for Q4 and FY
- Exactech (EXAC) reports Q3 EPS of $0.21; Guides
- Exactech Q3 Revenue $42.4M; Net Income $2.7M or $0.21 EPS
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
More News related to Downgrades
- BofA (BAC) Sells 1.286B Common Equivalent Securities at $15
- Puda Coal (PUDA) Files 191.3K Common Shelf For Selling Shareholders
- Bank of America (BAC) Raises $19.3B By Selling 'Common Equivalent Securities' at $15
- Home Properties (HME) Initiates 3.7M Common ATM Program
- SWS Group (SWS) Prices 4.35M Common Offering at $11.50/Share
Baird downgrades Exactech (Nasdaq: EXAC) from Outperform to Neutral. Price target lowered from $21 to $16.
Exactech, Inc. (Exactech) develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
